Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes.

Mega A, Aigner E, Turri C, Vittadello F, Dauriz M, Floreani A, Marzi L, Sacco R, Stasi C

Open source

DOI
10.23736/s0026-4806.26.09922-2
Published
2026 Aug
Container
Minerva medica
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.23736/s0026-4806.26.09922-2,
  title = {Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes.},
  author = {Mega A and Aigner E and Turri C and Vittadello F and Dauriz M and Floreani A and Marzi L and Sacco R and Stasi C},
  year = {2026},
  journal = {Minerva medica},
  doi = {10.23736/s0026-4806.26.09922-2},
  url = {https://doi.org/10.23736/s0026-4806.26.09922-2}
}

RIS

TY  - JOUR
TI  - Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes.
AU  - Mega A
AU  - Aigner E
AU  - Turri C
AU  - Vittadello F
AU  - Dauriz M
AU  - Floreani A
AU  - Marzi L
AU  - Sacco R
AU  - Stasi C
PY  - 2026
JO  - Minerva medica
DO  - 10.23736/s0026-4806.26.09922-2
UR  - https://doi.org/10.23736/s0026-4806.26.09922-2
ER  - 

APA

A, M., E, A., C, T., F, V., M, D., A, F., L, M., R, S., & C, S. (2026). Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes.. Minerva medica. https://doi.org/10.23736/s0026-4806.26.09922-2

Source records